Filtered By:
Cancer: Leukemia
This page shows you your search results in order of date. This is page number 18.
Order by Relevance | Date
Total 28367 results found since Jan 2013.
Immunotherapy for acute myeloid leukemia: current trends, challenges, and strategies
Acta Haematol. 2023 Sep 6. doi: 10.1159/000533990. Online ahead of print.ABSTRACTBACKGROUND: In the past decade, there have been significant breakthroughs in immunotherapies for B-cell lymphoid malignancies and multiple myeloma, but progress has been much less for acute myeloid leukemia (AML). Nevertheless, challenge begets innovation and several therapeutic strategies are under investigation.SUMMARY: In this review, we review the state of the art in AML immunotherapy including CD33- and CD123-targeted agents, immune checkpoint inhibition, and adoptive cell therapy strategies. We also share conceptual frameworks for approa...
Source: Acta Haematologica - September 6, 2023 Category: Hematology Authors: Evan C Chen Jacqueline S Garcia Source Type: research
LIF signaling regulates outer radial glial to interneuron fate during human cortical development
Cell Stem Cell. 2023 Aug 29:S1934-5909(23)00292-8. doi: 10.1016/j.stem.2023.08.009. Online ahead of print.ABSTRACTRadial glial (RG) development is essential for cerebral cortex growth and organization. In humans, the outer radial glia (oRG) subtype is expanded and gives rise to diverse neurons and glia. However, the mechanisms regulating oRG differentiation are unclear. oRG cells express leukemia-inhibitory factor (LIF) receptors during neurogenesis, and consistent with a role in stem cell self-renewal, LIF perturbation impacts oRG proliferation in cortical tissue and organoids. Surprisingly, LIF treatment also increases t...
Source: Cell Stem Cell - September 6, 2023 Category: Stem Cells Authors: Madeline G Andrews Clara Siebert Li Wang Matthew L White Jayden Ross Raul Morales Megan Donnay Gradi Bamfonga Tanzila Mukhtar Arpana Arjun McKinney Kaila Gemenes Shaohui Wang Qiuli Bi Elizabeth E Crouch Neelroop Parikshak Georgia Panagiotakos Eric Huang A Source Type: research
A case of Hodgkin lymphoma-type Richter syndrome presenting as small-intestinal perforation
Int J Hematol. 2023 Sep 6. doi: 10.1007/s12185-023-03655-2. Online ahead of print.ABSTRACTHodgkin lymphoma type of Richter syndrome (HL-type RS) is a rare disease that arises in patients with chronic lymphocytic leukemia (CLL). HL-type RS lesions can manifest in various sites and are often accompanied by related symptoms. This is the first case report to describe diagnosis of HL-type RS after emergency surgery for gastrointestinal perforation caused by the development of a HL-type RS lesion. A 47-year-old man diagnosed with CLL three years prior began treatment with ibrutinib due to worsening anemia and splenomegaly two mo...
Source: International Journal of Hematology - September 6, 2023 Category: Hematology Authors: Kosuke Miki Reiki Ogasawara Shunsuke Sugimura Junichi Sugita Rintaro Nozu Keisuke Kojima Daisuke Hidaka Ai Shimizu Kohei Okada Naoki Kobayashi Masahiro Ogasawara Masahiro Imamura Yoshihiro Matsuno Shuichi Ota Source Type: research
HLA Fully-Mismatched Sibling-Derived CD7 CAR-T Therapy Bridging to Haploidentical Hematopoietic Stem Cell Transplantation for Hepatosplenic γδ T-cell Lymphoma
Cell Transplant. 2023 Jan-Dec;32:9636897231194265. doi: 10.1177/09636897231194265.ABSTRACTWhile chimeric antigen receptor (CAR)-T-cell therapy has demonstrated remarkable effectiveness in the treatment of B-cell lymphomas and leukemias, research on T-cell malignancies is still limited. Here, we reported a patient with hepatosplenic γδ T-cell lymphoma refractory to multiple lines of chemotherapy, who eventually achieved first complete remission with flow cytometry-confirmed minimal residual disease negativity after human leukocyte antigen (HLA) fully-mismatched sibling-derived CD7 CAR-T therapy. However, given the allogen...
Source: Cell Transplantation - September 5, 2023 Category: Cytology Authors: Xueer Xu Cheng Zu Mingming Zhang Pingnan Xiao Ruimin Hong Jingjing Feng Huijun Xu Jiazhen Cui Jian Yu Jimin Shi Guoqing Wei Alex H Chang He Huang Yongxian Hu Source Type: research
Design and preclinical testing of an anti-CD41 CAR T cell for the treatment of acute megakaryoblastic leukaemia
J Cell Mol Med. 2023 Sep 4. doi: 10.1111/jcmm.17810. Online ahead of print.ABSTRACTAcute megakaryoblastic leukaemia (AMkL) is a rare subtype of acute myeloid leukaemia (AML) representing 5% of all reported cases, and frequently diagnosed in children with Down syndrome. Patients diagnosed with AMkL have low overall survival and have poor outcome to treatment, thus novel therapies such as CAR T cell therapy could represent an alternative in treating AMkL. We investigated the effect of a new CAR T cell which targets CD41, a specific surface antigen for M7-AMkL, against an in vitro model for AMkL, DAMI Luc2 cell line. The perf...
Source: J Cell Mol Med - September 5, 2023 Category: Molecular Biology Authors: Adrian Bogdan Tigu Catalin Sorin Constantinescu Patric Teodorescu David Kegyes Raluca Munteanu Richard Feder Mareike Peters Ioana Pralea Cristina Iuga Diana Cenariu Andra Marcu Alina Tanase Anca Colita Rares Drula Jon Thor Bergthorsson Victor Greiff Delia Source Type: research
HLA Fully-Mismatched Sibling-Derived CD7 CAR-T Therapy Bridging to Haploidentical Hematopoietic Stem Cell Transplantation for Hepatosplenic γδ T-cell Lymphoma
Cell Transplant. 2023 Jan-Dec;32:9636897231194265. doi: 10.1177/09636897231194265.ABSTRACTWhile chimeric antigen receptor (CAR)-T-cell therapy has demonstrated remarkable effectiveness in the treatment of B-cell lymphomas and leukemias, research on T-cell malignancies is still limited. Here, we reported a patient with hepatosplenic γδ T-cell lymphoma refractory to multiple lines of chemotherapy, who eventually achieved first complete remission with flow cytometry-confirmed minimal residual disease negativity after human leukocyte antigen (HLA) fully-mismatched sibling-derived CD7 CAR-T therapy. However, given the allogen...
Source: Cell Transplantation - September 5, 2023 Category: Cytology Authors: Xueer Xu Cheng Zu Mingming Zhang Pingnan Xiao Ruimin Hong Jingjing Feng Huijun Xu Jiazhen Cui Jian Yu Jimin Shi Guoqing Wei Alex H Chang He Huang Yongxian Hu Source Type: research
Design and preclinical testing of an anti-CD41 CAR T cell for the treatment of acute megakaryoblastic leukaemia
J Cell Mol Med. 2023 Sep 4. doi: 10.1111/jcmm.17810. Online ahead of print.ABSTRACTAcute megakaryoblastic leukaemia (AMkL) is a rare subtype of acute myeloid leukaemia (AML) representing 5% of all reported cases, and frequently diagnosed in children with Down syndrome. Patients diagnosed with AMkL have low overall survival and have poor outcome to treatment, thus novel therapies such as CAR T cell therapy could represent an alternative in treating AMkL. We investigated the effect of a new CAR T cell which targets CD41, a specific surface antigen for M7-AMkL, against an in vitro model for AMkL, DAMI Luc2 cell line. The perf...
Source: J Cell Mol Med - September 5, 2023 Category: Molecular Biology Authors: Adrian Bogdan Tigu Catalin Sorin Constantinescu Patric Teodorescu David Kegyes Raluca Munteanu Richard Feder Mareike Peters Ioana Pralea Cristina Iuga Diana Cenariu Andra Marcu Alina Tanase Anca Colita Rares Drula Jon Thor Bergthorsson Victor Greiff Delia Source Type: research
Design, synthesis, and evaluation of a mitoxantrone probe (MXP) for biological studies
Bioorg Med Chem Lett. 2023 Sep 3:129465. doi: 10.1016/j.bmcl.2023.129465. Online ahead of print.ABSTRACTMitoxantrone (MX) is a robust chemotherapeutic with well-characterized applications in treating certain leukemias and advanced breast and prostate cancers. The canonical mechanism of action associated with MX is its ability to intercalate DNA and inhibit topoisomerase II, giving it the designation of a topoisomerase II poison. Years after FDA approval, investigations have unveiled novel protein-binding partners, such as methyl-CpG-binding domain protein (MBD2), PIM1 serine/threonine kinase, RAD52, and others that may con...
Source: Bioorganic and Medicinal Chemistry Letters - September 5, 2023 Category: Chemistry Authors: Savanna Wallin Sarbjit Singh Gloria E O Borgstahl Amarnath Natarajan Source Type: research
Design and preclinical testing of an anti-CD41 CAR T cell for the treatment of acute megakaryoblastic leukaemia
J Cell Mol Med. 2023 Sep 4. doi: 10.1111/jcmm.17810. Online ahead of print.ABSTRACTAcute megakaryoblastic leukaemia (AMkL) is a rare subtype of acute myeloid leukaemia (AML) representing 5% of all reported cases, and frequently diagnosed in children with Down syndrome. Patients diagnosed with AMkL have low overall survival and have poor outcome to treatment, thus novel therapies such as CAR T cell therapy could represent an alternative in treating AMkL. We investigated the effect of a new CAR T cell which targets CD41, a specific surface antigen for M7-AMkL, against an in vitro model for AMkL, DAMI Luc2 cell line. The perf...
Source: Molecular Medicine - September 5, 2023 Category: Molecular Biology Authors: Adrian Bogdan Tigu Catalin Sorin Constantinescu Patric Teodorescu David Kegyes Raluca Munteanu Richard Feder Mareike Peters Ioana Pralea Cristina Iuga Diana Cenariu Andra Marcu Alina Tanase Anca Colita Rares Drula Jon Thor Bergthorsson Victor Greiff Delia Source Type: research
Design, synthesis, and evaluation of a mitoxantrone probe (MXP) for biological studies
Bioorg Med Chem Lett. 2023 Sep 3:129465. doi: 10.1016/j.bmcl.2023.129465. Online ahead of print.ABSTRACTMitoxantrone (MX) is a robust chemotherapeutic with well-characterized applications in treating certain leukemias and advanced breast and prostate cancers. The canonical mechanism of action associated with MX is its ability to intercalate DNA and inhibit topoisomerase II, giving it the designation of a topoisomerase II poison. Years after FDA approval, investigations have unveiled novel protein-binding partners, such as methyl-CpG-binding domain protein (MBD2), PIM1 serine/threonine kinase, RAD52, and others that may con...
Source: Bioorganic and Medicinal Chemistry Letters - September 5, 2023 Category: Chemistry Authors: Savanna Wallin Sarbjit Singh Gloria E O Borgstahl Amarnath Natarajan Source Type: research
Design and preclinical testing of an anti-CD41 CAR T cell for the treatment of acute megakaryoblastic leukaemia
J Cell Mol Med. 2023 Sep 4. doi: 10.1111/jcmm.17810. Online ahead of print.ABSTRACTAcute megakaryoblastic leukaemia (AMkL) is a rare subtype of acute myeloid leukaemia (AML) representing 5% of all reported cases, and frequently diagnosed in children with Down syndrome. Patients diagnosed with AMkL have low overall survival and have poor outcome to treatment, thus novel therapies such as CAR T cell therapy could represent an alternative in treating AMkL. We investigated the effect of a new CAR T cell which targets CD41, a specific surface antigen for M7-AMkL, against an in vitro model for AMkL, DAMI Luc2 cell line. The perf...
Source: Molecular Medicine - September 5, 2023 Category: Molecular Biology Authors: Adrian Bogdan Tigu Catalin Sorin Constantinescu Patric Teodorescu David Kegyes Raluca Munteanu Richard Feder Mareike Peters Ioana Pralea Cristina Iuga Diana Cenariu Andra Marcu Alina Tanase Anca Colita Rares Drula Jon Thor Bergthorsson Victor Greiff Delia Source Type: research
RNA binding protein IGF2BP1 synergizes with ETV6-RUNX1 to drive oncogenic signaling in B-cell Acute Lymphoblastic Leukemia
CONCLUSION: Our data suggest a combined impact of the ETV6::RUNX1 fusion protein and RNA binding protein, IGF2BP1 in activating multiple oncogenic pathways in B-ALL which makes IGF2BP1 and these pathways as attractive therapeutic targets and biomarkers.PMID:37670323 | DOI:10.1186/s13046-023-02810-1
Source: Cell Research - September 5, 2023 Category: Cytology Authors: Gunjan Sharma Tiffany M Tran Ishu Bansal Mohammad Sabique Beg Ruchi Bhardwaj Jaspal Bassi Yuande Tan Amit Kumar Jaiswal Christine Tso Ayushi Jain Jay Singh Parthaprasad Chattopadhyay Archna Singh Anita Chopra Sameer Bakhshi David Casero Dinesh S Rao Jayan Source Type: research
Design and preclinical testing of an anti-CD41 CAR T cell for the treatment of acute megakaryoblastic leukaemia
J Cell Mol Med. 2023 Sep 4. doi: 10.1111/jcmm.17810. Online ahead of print.ABSTRACTAcute megakaryoblastic leukaemia (AMkL) is a rare subtype of acute myeloid leukaemia (AML) representing 5% of all reported cases, and frequently diagnosed in children with Down syndrome. Patients diagnosed with AMkL have low overall survival and have poor outcome to treatment, thus novel therapies such as CAR T cell therapy could represent an alternative in treating AMkL. We investigated the effect of a new CAR T cell which targets CD41, a specific surface antigen for M7-AMkL, against an in vitro model for AMkL, DAMI Luc2 cell line. The perf...
Source: J Cell Mol Med - September 5, 2023 Category: Molecular Biology Authors: Adrian Bogdan Tigu Catalin Sorin Constantinescu Patric Teodorescu David Kegyes Raluca Munteanu Richard Feder Mareike Peters Ioana Pralea Cristina Iuga Diana Cenariu Andra Marcu Alina Tanase Anca Colita Rares Drula Jon Thor Bergthorsson Victor Greiff Delia Source Type: research
